Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemiaHeikki Kuusanmäki, Caroline A. Heckman|Haematologica|2019Cited by 184
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AMLRiikka Karjalainen, Caroline A. Heckman|Blood|2017Cited by 122
The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and LymphangiogenesisCaroline A. Heckman, Kari Alitalo|Cancer Research|2008Cited by 117
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signalingHeikki Kuusanmäki, Caroline A. Heckman|Oncotarget|2017Cited by 31
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidineMahesh Tambe, Caroline A. Heckman|Cell Death and Disease|2024Cited by 9